In recipients of hematopoietic stem cell transplants (HSCTs), BK virus (BKV) has been associated with late-onset hemorrhagic cystitis (HC). In our institution, HSCT recipients with BKV-associated HC are treated with 1 mg/kg of cidofovir weekly. We identified HSCT recipients with BKV-associated HC, treated with weekly cidofovir. Microbiological response was defined as at least a one log reduction in urinary BKV viral load; clinical response was defined as improvement in symptoms and stability or reduction in the grade of cystitis. Nineteen allogeneic HSCT patients received a mean of 4.5 weekly doses of cidofovir. HC occurred at a mean of 68.7 days after transplant. A clinical response was detected in 16/19 (84%) patients, and 9/19 (47%) had a measurable microbiological response (8/10 nonresponders had a BKV viral load above the upper limit of the assay before treatment). Fourteen out of nineteen (74%) patients had no significant increase in serum creatinine. Five patients with renal dysfunction resolved after completion of the therapy and removal of other nephrotoxic agents. We conclude that weekly low-dose cidofovir appears to be a safe treatment option for BKV-associated HC. AlthoughIntroduction BK virus (BKV) is a human polyomavirus acquired in childhood, which remains latent in the genitourinary tract throughout life. 1 BKV has been associated with ureteral stenosis and graft failure in renal transplant recipients, and in 1986 Arthur et al. 1, 2 reported an association between BKV viruria and hemorrhagic cystitis (HC) in recipients of bone marrow transplants. HC complicates the course of 7-40% of recipients of hematopoietic stem cell transplants (HSCTs); early onset disease is probably secondary to the conditioning regimen and later onset disease has been associated with viral pathogens. 1, [3] [4] [5] [6] Polymerase chain reaction (PCR) can detect BKV in up to 95% of patients at some point after allogeneic HSCT 7 and this has been used for diagnosis and for monitoring during treatment of the disease. 5, [7] [8] [9] Most of these patients do not develop clinically significant HC, but patients with higher viral loads in the urine or plasma as assessed by quantitative PCR appear to be at increased risk of developing HC. [6] [7] [8] [9] [10] Cidofovir (HPMPC) is a cytosine derivative of an acyclic nucleoside-phosphonate analogue, which has broad-spectrum activity against many DNA viruses including cytomegalovirus (CMV), adenoviruses and polyomaviruses. 11, 12 Low-dose cidofovir (0.25-1.5 mg/kg) has been used successfully in the management of BKV nephropathy. [13] [14] [15] [16] Although no standard treatment of BKVassociated HC exists, others have described previously the use of intravenous cidofovir at varying doses in HSCT patients with late-onset HC with variable results. 4, 5, [17] [18] [19] Given the paucity of established treatment options, lowdose cidofovir (1 mg/kg) without probenicid has been given weekly at our institution for BKV-associated HC. In efforts to determine if further study of low-dose cidofovir therapy for BKV-associated HC is warranted, the safety profile and the microbiological and clinical outcomes with use of this regimen were investigated. Cidofovir was always given as a 1-mg/kg weekly dose without probenicid and serum creatinine was obtained at least weekly. Quantitation of BKV was based on the realtime qPCR amplification and detection of BKV genomic DNA. The assay ranged from a lower limit of 200 BKV DNA copies/ml to an upper limit of 2 Â 10 8 BKV DNA copies/ml. The coefficient of variation for the assay was 21% at 9 Â 10 6 copies/ml with a standard deviation71.9 Â 10 6 copies/ml (Focus Technologies Inc., Cypress, CA, USA). Microbiologic response was defined as at least one log reduction in BKV viral load by qPCR and was assayed within 2 weeks of completion of treatment. Clinical response was defined as (1) subjective improvement in the patient's symptoms and (2) a reduction or stability in the grade of cystitis. Given the consequences of obstructive uropathy in this patient population, if pretreatment HC was grade 3 or 4, only patients with improvement in the grade of cystitis were counted as clinical responses. Nephrotoxicity was defined as a 0.3 mg/dl or greater increase in serum creatinine at any time during and up to 2 weeks after any treatment with cidofovir.
Methods
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Nineteen HSCT patients with a mean age of 42 years were included. All patients had allogeneic transplants from variable donor sources for a wide variety of malignant processes. The rate of graft-versus-host disease (GVHD) in the overall population of allogeneic HSCT at our institution was 52% (79/151) during this time period and 84% (16/19) of this cohort had documented GVHD. All patients with GVHD in this cohort were on steroids (methylprednisone 1.0-2.0 mg/kg daily) at the time of diagnosis of HC, the grade of the GVHD is reported in Table 1 . The patients received a mean of 4.5 weekly doses of cidofovir (range 3-8 doses). HC developed at a mean of 68.7 days after transplant (18-215 days) .
In the safety analysis, 14/19 patients (74%) had no significant increase in serum creatinine (i.e., increase less than 0.3 mg/dl). The remaining five patients all had other possible causes of acute renal failure (e.g., obstructive uropathy secondary to HC, hypovolemia, sepis, other nephrotoxic agents). Renal failure resolved despite continuing the cidofovir in two patients. Two patients required hospitalization for renal failure and one was found to have obstructive uropathy from HC and the other had nephrotic syndrome felt to be secondary to GVHD of the kidney or cidofovir. The fifth patient had an increase of 0.5 mg/dl in serum creatinine after receiving three doses of cidofovir. Concurrent possible causes of renal failure for this patient included liposomal amphotericin, elevated tacrolimus levels and sepsis. In this case, renal function returned to baseline with clinical improvement after withdrawal of nephrotoxins.
Nearly all patients had verifiable clinical response with use of cidofovir (16/19, 84%), but less than half of the patients developed a measurable microbiologic response (9/19, 47%). Of those who had no measurable microbiologic response, 8/10 had more than 2.0 Â 10 8 DNA copies/ml (the upper limit of detection with the assay used) both before and after therapy. Two patients had worsening of quantitative BKV viral loads while on therapy, yet resolution of symptoms and hematuria. All patients with a microbiological response had a clinical response (Table 2) .
Of note, five patients treated with cidofovir who had grade 3 HC with symptoms and BKV greater than 10 5 copies/ml were not included in the analysis as post-therapy viral titers were not assessed. All five of these patients had complete resolution of their HC after four doses of cidofovir without renal compromise as defined previously. Coinfection with other viruses, known to lead to HC after HCST, was also investigated. There were no cases of adenovirus in the urine in the 9/19 patients who were tested for adenovirus. CMV in the urine was assayed in 15/19 patients. The one patient with CMV in the urine had a clinical response from BKV-associated HC, but died of systemic CMV disease.
Discussion
Most patients in our study with BKV-associated HC tolerated low-dose cidofovir without probenicid without renal compromise or worsening of BKV-associated HC. Low-dose cidofovir appears to be generally safe in this population, but may have contributed to renal failure in three of 19 (16%) of patients. In addition, all patients with a successful microbiological response had a successful clinical response. However, patients treated with low-dose cidofovir may fail, as evidenced by two patients without clinical improvement of their HC despite four or seven doses of cidofovir.
The pharmacokinetics of cidofovir have been evaluated in patients with CMV infection. [21] [22] [23] [24] [25] After 1 h infusions of 1, 3, 5, 7.5 and 10 mg/kg, the drug demonstrated doseindependent pharmacokinetics both with and without probenecid. Without probenecid, in patients with normal renal function, approximately 80-100% of the cidofovir dose was recovered unchanged in urine within 24 h, whereas approximately 70-85% of cidofovir was excreted within 24 h in patients who were also given probenicid. Thus, withholding probenicid may achieve higher urinary concentrations of cidofovir. The rapid clearance of cidofovir from the urine raises the question of whether more frequent dosing of intravenous or intravesicular instillation would be effective. Two studies describing intravesicular instillation of cidofovir for HC caused by BKV or adenovirus have been reported. Bridges et al. 26 describe a single patient with severe HC who improved with two weekly doses of 5 mg/kg intravesicularly administered cidofovir in 60 ml of normal saline with clamping of the foley catheter for 1 h after administration. A similar strategy has been used to treat successfully adenovirusassociated HC. 27 The outcome of BKV-associated HC is poorly understood; however, cases of spontaneous recovery with only supportive treatment have been described. 3, 5 It is possible that some of the patients in this study would have improved clinically without treatment. The upper limit of detection of the assay was 2 Â 10 8 copies/ml. Peak BKV viral loads in the urine as high as 1 Â 10 14 copies/ml have been reported in other studies. 7 As eight of our patients, who were considered microbiologic failures by the criteria listed above, had pre-and post-treatment BKV viral load beyond the upper limit of detection of our assay, the true microbiological response rate may be underestimated.
As mentioned above, there is some evidence that cidofovir has activity against other viral etiologies of HC.
Ideally, we would prefer to study the urine before and after treatment for CMV or adenovirus. The prevalence of these viruses among those assayed, however, seem to indicate that they did not contribute substantially to the etiology of HC in this study.
No standard treatment for BKV-associated HC is available. In addition to intravenous low-dose cidofovir, reported treatments include hyperhydration, intravesicular prostaglandins, continuous bladder irrigation, embolization of the vesicular artery and vidarabine. 1, 3, 7, 18 To our knowledge, five reports of intravenous cidofovir for BKVassociated HC have been published (Table 3) . 4, 5, [17] [18] [19] Four are single case reports and the case series did not include adults or quantitative BKV viral monitoring of the urine. No report used low-dose cidofovir and probenicid was used in each case. Three of the four case reports describe clinical and microbiological success; one describes worsening after two doses. Our report is the largest available and the only using the 1 mg/kg dose without probenicid with serial microbiological monitoring.
BKV may play a substantial role in late-onset HC in the HSCT patient population. Low-dose cidofovir without probenecid is an attractive treatment option, as it may reduce the renal toxicity of standard dose cidofovir in these patients. The presence of GVHD, multiple comorbidities (e.g., thrombocytopenia) and the variable natural history of BKV-associated HC complicate the conduct of clinical trials. Our results do suggest, however, that proceeding to a prospective trial of low-dose cidofovir for the treatment of BKV-associated HC is warranted.
